The study is concerned with the mechanism of activation of soluble guanylate cycla-se by guanidine thiol derivatives-a new class of enzyme activators. Guanidine thiols contain both the guanidine and SH group which act, respectively, as donor and acceptor of nitric oxide (NO). The role of guanidine thiol SH group in the mechanism of soluble guanylate cyclase activation was studied. Three guanidine thiol derivatives were tested: mercaptoethylguanidine, its disulfide and S-methyl mercaptoethylguani-dine. All three compounds proved to be NO-synthase substrates and, simultaneously, guanylate cyclase activators. The degrees of guanylate cyclase activation by mercaptoethylguanidine and its disulfide were, respectively, two and four times higher than that by L-arginine. The stimulatory effects of S-methyl mercaptoethylguanidine and L-arginine were evaluated and found to be of the same order. The important role of S-acceptor group of guanidine thiols in the mechanism of guanylate cyclase activation increase provides an explanation for different intensities of guanylate cyclase activation by the compounds tested. NO-acceptor properties of guanidine thiols disulfide bonds in the synthase mechanism of NO generation were first reported.

Download full-text PDF

Source

Publication Analysis

Top Keywords

guanylate cyclase
24
cyclase activation
16
soluble guanylate
12
guanidine thiol
12
guanidine thiols
12
mechanism activation
8
activation soluble
8
guanidine
8
class enzyme
8
enzyme activators
8

Similar Publications

The conserved MAP3K DLKs are widely known for their functions in synapse formation, axonal regeneration and degeneration, and neuronal survival, notably under traumatic injury and chronic disease conditions. In contrast, their roles in other neuronal compartments are much less explored. Through an unbiased forward genetic screening in C.

View Article and Find Full Text PDF

Introduction: Vericiguat, an oral stimulator of soluble guanylate cyclase, reduces cardiovascular mortality and hospitalisations in patients with heart failure (HF) and reduced ejection fraction, as demonstrated in the VICTORIA trial. This study assessed the real-world use of vericiguat.

Material And Methods: This cross-sectional, prospective and multicenter registry (VERISEC) included 776 patients from 43 centres in Spain between December 2022 and October 2023.

View Article and Find Full Text PDF

Purpose: To investigate the effects of C-type natriuretic peptide (CNP) on human granulosa cell growth and elucidate its regulatory mechanisms.

Methods: A human non-luteinizing granulosa cell line (HGrC) developed from small antral follicles was used to assess the impact of CNP on cell proliferation and estrogen synthesis. cGMP production via the guanylate cyclase domain of the CNP receptor, natriuretic peptide receptor 2 (NPR2), was confirmed.

View Article and Find Full Text PDF

Soluble guanylate cyclase stimulators and activators as potential antihypertensive drugs.

Hypertens Res

January 2025

Department of Pathological and Molecular Pharmacology, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.

Poor blood pressure control in treated patients with hypertension is an important topic in the field of hypertension, and an unmet need for new therapeutic drugs remains. Soluble guanylate cyclase (sGC), a key signal transduction enzyme responsible for vasodilation, has attracted increasing interest as a therapeutic target in various cardiovascular diseases. Two different sGC agonists, sGC stimulators and activators, can increase its enzymatic activity in reduced and oxidized/apo forms, respectively.

View Article and Find Full Text PDF

Novel Therapies for Right Ventricular Failure.

Curr Cardiol Rep

January 2025

Pediatric Advanced Heart Failure and Heart Transplant Program, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA.

Purpose Of Review: Traditionally viewed as a passive player in circulation, the right ventricle (RV) has become a pivotal force in hemodynamics. RV failure (RVF) is a recognized complication of primary cardiac and pulmonary vascular disorders and is associated with a poor prognosis. Unlike treatments for left ventricular failure (LVF), strategies such as adrenoceptor signaling inhibition and renin-angiotensin system modulation have shown limited success in RVF.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!